Sagawa, Zachary K.
Goman, Cristina
Frevol, Aude
Blazevic, Azra
Tennant, Janice
Fisher, Bridget
Day, Tracey
Jackson, Stephen
Lemiale, Franck
Toussaint, Leon
Kalisz, Irene
Jiang, Joe
Ondrejcek, Lisa
Mohamath, Raodoh
Vergara, Julie
Lew, Alan
Beckmann, Anna Marie
Casper, Corey http://orcid.org/0000-0002-3609-661X
Hoft, Daniel F.
Fox, Christopher B. http://orcid.org/0000-0002-4644-2619
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400041C)
Article History
Received: 23 December 2022
Accepted: 16 February 2023
First Online: 6 March 2023
Competing interests
: C.B.F. declares no competing non-financial interests but the following competing financial interests. C.B.F. is co-inventor on patents claiming priority to WO/2015/103167, single-vial vaccine formulations, and WO/2013/119856, improved adjuvant formulations comprising TLR4 agonists and methods of using the same. The remaining authors declare no competing interests.